Condition: Multiple Myeloma · Sponsor: Celgene
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Yale New Haven Hospital-Smilow Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Hackensack University Medical Center | Hackensack, New Jersey, United States | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Arthur J E Child Comprehensive Cancer Centre | Calgary, Alberta, Canada | Recruiting |
| Local Institution - 0026 | Vancouver, British Columbia, Canada | Not Yet Recruiting |
| QEII Health Sciences Centre - Victoria General Site | Halifax, Nova Scotia, Canada | Recruiting |
| Princess Margaret Cancer Centre | Toronto, Ontario, Canada | Recruiting |
| Local Institution - 0030 | Suzhou, Jiangsu, China | Not Yet Recruiting |
| Local Institution - 0031 | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
| Universitaetsklinikum Carl Gustav Carus Dresden | Dresden, Germany | Recruiting |
| Universitaetsklinikum Hamburg-Eppendorf | Hamburg, Germany | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06988488